News & Updates
Filter by Specialty:
SGLT-2 inhibitors help avert death in patients with HFrEF
Use of SGLT-2 inhibitors may reduce the risk of all-cause and cardiovascular (CV) mortality in patients with heart failure (HF) with reduced ejection fraction (HFrEF), reports a study.
SGLT-2 inhibitors help avert death in patients with HFrEF
19 Nov 2024
Trastuzumab deruxtecan improves PFS in metastatic breast cancer, but ups ILD risk
Treatment with trastuzumab deruxtecan (T-DXd) demonstrates efficacy in patients with metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) breast cancer but may result in adverse events, such as interstitial lung disease (ILD), suggests a study.
Trastuzumab deruxtecan improves PFS in metastatic breast cancer, but ups ILD risk
18 Nov 2024
Sacituzumab govitecan improves survival in advanced breast cancer
Treatment with sacituzumab govitecan (SG), a novel antibody-drug conjugate, provides survival benefits in women diagnosed with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) breast cancer, reports a study.
Sacituzumab govitecan improves survival in advanced breast cancer
18 Nov 2024
Socioeconomic status tied to low use of adjuvant immunotherapy in stage III melanoma
Patients with stage III melanoma show inconsistent use of adjuvant immunotherapy despite its survival benefits, according to a study.
Socioeconomic status tied to low use of adjuvant immunotherapy in stage III melanoma
17 Nov 2024
Topical estriol gel prevents UTI, improves vaginal health in postmenopausal women
Ultra-low-dose 0.005 % estriol vaginal gel helps reduce the incidence of recurrent urinary tract infections (UTIs) and improve vaginal pH in postmenopausal women with genitourinary syndrome of menopause (GSM), as reported in a study.